SENIOR ‐ IPI : An easily applicable prognostic index for first‐line large B‐cell lymphomas patients >80 years treated with curative intent
Open Access
- 27 September 2026
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 209 (5) , 2073-2082
Abstract
Summary: Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen. SENIOR‐International Prognostic Index (SENIOR‐IPI) takes into account accessible variables (number of aaIPI predictors, lactate dehydrogenase > 3x Upper Limit of Normal (LDH >3× ULN), albumin 80 years old fit for age‐adapted immunochemotherapy than IPI, aaIPI and NCCN‐IPI.Keywords
This publication has 33 references indexed in Scilit:
- 160 | VERLen: TAFASITAMAB, LENALINOMIDE, PLUS RITUXIMAB IN FRONTLINE DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS OVER 80 Y/O OR OLDER, A LYSA PHASE 2 TRIALHematological Oncology, 2025
- R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based studyAmerican Journal of Hematology, 2023
- Low serum albumin is an independent risk factor in elderly patients with aggressive B‐cell lymphoma: Results from prospective trials of the German High‐Grade Non‐Hodgkin's Lymphoma Study GroupeJHaem, 2020
- A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic ImplicationsCancer Cell, 2020
- Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA groupThe Lancet Haematology, 2017
- Serum albumin level at diagnosis of diffuse large B‐cell lymphoma: an important simple prognostic factorHematological Oncology, 2015
- Comparing two correlated C indices with right‐censored survival outcome: a one‐shot nonparametric approachStatistics in Medicine, 2014
- Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2011
- SAS and R functions to compute pseudo-values for censored data regressionComputer Methods and Programs in Biomedicine, 2008
- Immunoglobulin VH Gene Expression in Human AgingClinical Immunology, 1999